However, trial therapy in the centrally reviewed population was consistently associated with significant multivariate DFS (P = 0.002 to 0.005), in all centrally reviewed patients, and in the subgroup of women whose tumours had positive IHC stain for ER and/or PgR. This evidence concerns the gene ESR1 and neoplasm.